Synopsis: Hester Biosciences Limited reported a strong performance in Q4 FY26, driven by sharp improvement in profitability and healthy growth in revenue. The company posted consolidated revenue from operations of Rs. 100.11 crore in Q4 FY26, compared to Rs. 81.93 crore reported in Q4 FY25, reflecting a growth of around 22% year-on-year. Along with the quarterly results, the company also recommended a dividend of Rs. 11 per equity share for FY26.
Hester Biosciences Limited is one of India’s leading animal healthcare companies engaged in manufacturing vaccines and health products for poultry, large animals, and pet care segments. The company operates across vaccine production, animal health diagnostics, and pharmaceutical formulations. The company has built a strong presence in domestic as well as international markets through its focus on animal healthcare innovation, preventive vaccination, and integrated veterinary solutions.
As of May 2026, Hester Biosciences has a market capitalization of Rs. 1,563 crore. The stock is currently trading around Rs. 1,831 per share, up by 5.30% compared to previous close of Rs. 1,740, compared to its 52-week high of Rs. 2,350 and 52-week low of Rs. 1,239. The company has a ROCE of 9.71% and ROE of 9.18%, while the stock trades at a P/E ratio of 38.2. Hester Biosciences also offers a dividend yield of 0.37%.
Hester Biosciences reported revenue from operations of Rs. 100.11 crore in Q4 FY26, registering a growth of around 29% QoQ compared to Rs. 77.42 crore reported in Q3 FY26. On a year-on-year basis, revenue increased by nearly 22% from Rs. 81.93 crore reported in Q4 FY25.
Total income for the quarter stood at Rs. 97.08 crore compared to Rs. 78.08 crore in the December quarter and Rs. 74.98 crore in the year-ago quarter. The company reported total expenses of Rs. 76.79 crore during Q4 FY26 against Rs. 65.88 crore in Q3 FY26.
Profit before tax stood at Rs. 25.08 crore compared to Rs. 13.52 crore reported in the previous quarter. Hester Biosciences posted a net profit of Rs. 16.55 crore in Q4 FY26, reflecting a strong 78% QoQ growth from Rs. 9.31 crore reported in Q3 FY26. On a year-on-year basis, profit surged sharply from Rs. 1.54 crore reported in Q4 FY25.
The board of directors recommended a dividend of Rs. 11 per equity share having a face value of Rs. 10 each for FY2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM).
India’s healthcare sector is expected to witness strong long-term growth driven by rising healthcare spending, increasing demand for medical infrastructure, and expanding access to quality healthcare services. According to the Economic Survey 2024-25, public healthcare expenditure is expected to reach 1.9% of GDP in FY26. By 2030, India is projected to require nearly 3 million additional hospital beds along with 1.54 million doctors and 2.4 million nurses to meet rising healthcare demand.
The sector is also attracting significant investments and policy support. Private equity investments in Indian healthcare touched around Rs. 4,900 crore across 33 deals in Q2 CY25. Additionally, the Union Budget 2025-26 allocated Rs. 99,858 crore to the healthcare sector, reflecting continued government focus on strengthening healthcare infrastructure, workforce development, and positioning India as a global healthcare hub.
Hester Biosciences delivered a strong Q4 FY26 performance with robust revenue growth and a sharp surge in profitability. The company’s improving operational performance, strong presence in animal healthcare, and dividend announcement indicate positive momentum going forward.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Hester Biosciences Limited Stock Jumps 5% After Reporting 974% YoY Profit Surge in Q4; Announces ₹11 Dividend appeared first on Trade Brains.